NPR·51 signal
HHS will let pharmacies make popular peptides not approved by the FDAHealth Policy October 29, 20264:45 AM ET Heard on Morning Edition ...
Original sourceBPOPNASDAQFinancial Services
POPULAR INC
Public company snapshot, recent ticker-linked headlines, and a path into evidence-backed AI research.
Latest price
$156.52
+0.29%
Alpha Vantage · 11/6/2026
Industry: Banks - RegionalCategory: Domestic Common Stock Primary ClassCurrency: USDNews: 2 recent
Analyze BPOP free One-year price history
Adjusted daily closes · 252 observations · as of Nov 6, 2026
1 month
+0.5%
3 months
-9.5%
6 months
+6.2%
1 year
+42.1%
Year to date
+27.8%
52-week range
$107.66 – $176.90
Fundamental snapshot
Latest reported period: Jun 30, 2026
Market cap
$9.98B
P/E
10.3
P/B
1.6
P/S
3.3
Revenue
$3.06B
Net income
$967.69M
Diluted EPS
14.79
Gross margin
100.00%
Net margin
31.60%
Return on equity
15.40%
Total debt
$1.46B
Cash
$4.92B
Free cash flow
$912.09M
Latest eight reported quarters
Reported quarterly values, newest first
| Period | Revenue | Net income | Gross margin | Net margin | Free cash flow |
|---|---|---|---|---|---|
| Jun 30, 2026 | $808.09M | $277.86M | 100.00% | 34.40% | $347.15M |
| Mar 31, 2026 | $759.92M | $245.32M | 100.00% | 32.30% | $155.21M |
| Dec 31, 2025 | $751.82M | $233.55M | 100.00% | 31.10% | $268.47M |
| Sep 30, 2025 | $742.58M | $210.96M | 100.00% | 28.40% | $141.25M |
| Jun 30, 2025 | $751.09M | $210.09M | 100.00% | 28.00% | $198.41M |
| Mar 31, 2025 | $693.58M | $177.15M | 100.00% | 25.50% | $120.73M |
| Dec 31, 2024 | $689.36M | $177.46M | 100.00% | 25.70% | $199.48M |
| Sep 30, 2024 | $665.11M | $154.97M | 100.00% | 23.30% | $176.72M |
Reported figures can reflect company reporting conventions, restatements, or sector-specific accounting. Verify against filings before relying on a valuation comparison.
Recent BPOP news
All market newsNPR·48 signal
Trump administration will allow pharmacies to make popular peptidesThe Department of Health and Human Services will let small compounding pharmacies make six peptides that haven't been approved by the Food and Drug Administration. It may not be enough to meet demand.
Original source